Navigation Links
Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose

Once-daily nevirapine (Viramune) is associated with a higher risk of rash, leading to treatment discontinuation or interruption//, than twice-daily dosing of the drug, according to Canadian research published in the January edition of HIV Medicine. The investigators also found that individuals who took nevirapine once daily were more likely to experience liver complications than patients who took the drug twice a day. For these reasons, the authors conclude that once-daily nevirapine cannot be recommended.

Once-daily dose of antiretroviral therapy is becoming increasingly available, and may be a way of improving patient adherence to treatment. Nevirapine has a long plasma half-life and high steady state plasma concentrations meaning that it may be a suitable candidate for once-daily use.

To determine how suitable the drug is for use on a once-daily basis, investigators from Ottawa conducted a literature review to establish the pharmacokinetics, efficacy and safety of once-daily nevirapine (400mg once a day) versus twice-daily (200mg twice a day) dose of the drug.

A Medline search was performed to identify published, peer-reviewed studies examining this question. Abstracts from major international HIV meetings were also reviewed.

The pharmacokinetic data suggested that once-daily nevirapine dosing resulted in lower minimum nevirapine plasma concentrations compared with twice-daily treatment. However these studies theoretically support once-daily dosing assuming that optimal adherence was maintained.

Several clinical trials have evaluated the safety and efficacy of nevirapine in a once-daily dosing regimen. The 2NN study is the largest and best known of these. The Canadian reviewers therefore focused on once-daily and twice-daily nevirapine recipients enrolled in the 2NN study.

The investigators found that the proportion of treatment failures by, or before, week 48 of the 2NN study were comp arable between the once-daily and twice-daily treated patients.

However, they also found that there was a trend for patients who were taking the drug once daily to be more likely to change therapy than those who were taking a twice-daily dose of nevirapine (29% versus 22%). They suggest that this could be because of a greater incidence of side-effects.

More patients experienced liver abnormalities in the once-daily group compared with twice-daily nevirapine (14% versus 8%; p=0.036). Also more patients in the once-daily group temporarily or permanently discontinued therapy because of rash (12% versus 7%).

Other smaller clinical trials were considered in the review. Each found that there was no statistically significant difference in the efficacy of once-daily and twice-daily nevirapine. In two of these studies there were also no differences in the frequency of adverse events between once and twice-daily regimens. A further study did, however, highlight a difference in frequency of adverse events between once- and twice-daily dosing of nevirapine.

This study involved 196 patients to investigate the safety and efficacy of switching from various twice-daily regimens (with or without nevirapine) to once-daily nevirapine (400mg), ddI (400mg) and tenofovir (300mg). In this study, adverse events leading to treatment discontinuation were more common in the once-daily group. After 48 weeks, three patients (4%) who continued twice-daily dosing stopped therapy versus twelve individuals (14%) who switched to once-daily dosing. The reasons for treatment discontinuation were: five cases of nevirapine-related hepatitis, two of acute pancreatitis, two of skin rash, two of dry mouth and one of peripheral neuropathy.

“Unfortunately, when compared with twice-daily dosing, antiretroviral regimens in which nevirapine is dosed at 400mg once daily immediately after a 2-week lead-in period are associated with an increased risk of rash leading to treatment interruption or discontinuation”, comment the investigators, adding, “the risk of liver complications is another lingering concern. For these reasons, once-daily nevirapine cannot be recommended at this time.”

The investigators do not, however, rule out the possibility of once-daily nevirapine use. They suggest that longer-term use of the drug could yield improved tolerance of higher concentrations of the drug. They write, “it is theoretically possible that the benefits of once-daily dosing can be achieved without excess toxicity by switching to once-daily nevirapine only after several months of twice-daily administration.”

Source-Bio-Bio Technoloy

'"/>




Related medicine news :

1. New Dietary Approach To Manage Kidney Stones
2. Approaching through Telemedicine benefits patients
3. Gel Offers A More Targeted Approach
4. New Cost Effective Approach To Promote Sun Protection
5. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
6. A New Approach In Treatment Neurogenic Detrusor Overactivity In Children
7. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
8. Lazy Eye Can Be Effectively Treated By New Approach
9. Novel Approach to Identify Protein Links with Genetic Disorder
10. NHS To Be Reformed By Using A Hybrid Approach
11. Two-In One Approach To Prevent Incontinence After Prolapse Surgery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition ... Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... , April 29, 2016 ... Directeur Financier Sanofi, leader ... publie ses résultats pour le premier ... Groupe, Jérôme Contamine, commente les résultats ... les perspectives pour le reste de ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology: